Management Comment "Finally, we’re advancing our immuno-oncology programs which phase 1 clinical trial of TSR-042 starting this quarter. We will submit the IND for TSR-022 in Q2 and we expect to select the clinical candidate targeting LAG-3 during the first half of this year.  By year end we intend to identify dosing schedule for TSR-042 as well as select five specific clinical candidate targeting PD-1 TIM-3 and PD-1 LAG-3."
-CEO Lonnie Moulder